Silexion Therapeutics Corp

Nasdaq:SLXNNasdaq:SLXNW

Biological Products, (No Diagnostic Substances)·RAMAT GAN, L3

CEO

Hadar Ilan

CFO

Horenshtein Hadar Mirit

Summary Financials

Revenue

—

Adj. EBITDA

-$4.6M

FY 2024

Net Income

-$5.1M

FY 2024

EPS (Diluted)

$44.23

FY 2024

Stock Price

$1.71

+3.6%

2026-03-06

52W Range

$1.42 – $22.36

P/E Ratio

0.0x

Market Cap

$5.3M

Cash

$4.6M

FY 2024

Total Debt

—

Net Cash

$4.6M

Enterprise Value

$751,557.82

Debt / EBITDA

1.0x

FY 2024

EV / EBITDA

-0.2x

Employees

—

Revenue

—

Adj. EBITDA

-$4.6M

FY 2024

Net Income

-$5.1M

FY 2024

EPS (Diluted)

$44.23

FY 2024

Stock Price

$1.71

+3.6%

2026-03-06

52W Range

$1.42 – $22.36

P/E Ratio

0.0x

Market Cap

$5.3M

Cash

$4.6M

FY 2024

Total Debt

—

Net Cash

$4.6M

Enterprise Value

$751,557.82

Debt / EBITDA

1.0x

FY 2024

EV / EBITDA

-0.2x

Employees

—